CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Extended Varenicline Pretreatment +1 moredrug
Likely dose
Extended Varenicline Pretreatment 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00860028
NCT00860028Phase 2Completed

Varenicline for Smoking Cessation in Heavy Drinking Smokers

Yale University·interventional·Posted Mar 11, 2009·Updated Aug 13, 2021

In Brief

A Phase 2 clinical trial evaluating Extended Varenicline Pretreatment and Short-term Varenicline Pretreatment for Nicotine Dependence and 2 related conditions. Completed, enrolled 30 participants.

Detailed Summary

The purpose of this study is to determine whether extended pretreatment with varenicline (Chantix) is more efficacious for smoking cessation than standard pretreatment, how well varenicline is tolerated in heavy drinking smokers, and whether varenicline reduces alcohol consumption.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 11, 2009
Enrollment StartOct 1, 2008
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.3 years ago

Interventions

Extended Varenicline Pretreatmentdrug

4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.

Short-term Varenicline Pretreatmentdrug

3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.